GlassScriptPhysician profile
Rahim A Remtulla
NPI 1881899128
$50,097.63
in general payments reported to CMS, 2019-2025
23 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,951 · 2020: $11K · 2021: $3,939 · 2022: $1,110 · 2023: $7,927 · 2024: $8,433 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $857 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,375.00 |
| Food and Beverage | $857.11 |
| Education | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $23,600.00 | 2023-2025 | |
| Mylan Institutional INC. | $6,820.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $5,628.11 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Verastem, INC. | $5,161.87 | 2019 | |
| Karyopharm Therapeutics INC. | $2,250.00 | 2021 | |
| Abbvie INC. | $2,200.00 | 2020 | |
| Dendreon Pharmaceuticals LLC | $1,635.22 | 2019 | |
| Secura Bio, INC. | $1,598.45 | 2020 | |
| Exelixis INC. | $169.51 | 2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $145.42 | 2025 | Onivyde |
| Intuitive Surgical, INC. | $124.46 | 2024 | |
| Ethicon INC. | $122.78 | 2020 | |
| Merck Sharp & Dohme LLC | $120.58 | 2024 | Lynparza |
| Incyte Corporation | $99.00 | 2023 | |
| Tesaro, INC. | $92.79 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $83.02 | 2025 | |
| Astellas Pharma US INC | $64.99 | 2020 | |
| Pfizer INC. | $59.86 | 2025 | |
| Beone Medicines USA, INC. | $29.24 | 2025 | Brukinsa |
| Celgene Corporation | $26.94 | 2025 | Breyanzi |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Sun Pharmaceutical Industries INC. | $19.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahim Remtulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.